U.S. regulators should consider pursuing misdemeanor charges against drug company executives for promoting unauthorized uses of their medicines, Food and Drug Administration Deputy Chief for Litigation Eric Blumberg said.
Blumberg spoke today at a conference of drug industry lawyers in Washington and didn’t offer a timetable for the agency to act.
To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net
To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net
via bloomberg.com
No comments:
Post a Comment